VSV-EBOVAC Project VSV-EBOVAC Project

Welcome to VSV-EBOVAC Project

VSV-EBOVAC  - Vaccine safety and immunogenicity signatures of human responses to rVSV-ZEBOV - is a collaborative research programme aimed to characterize the immune response elicited in humans by the Vesicular Stomatitis Virus (VSV)-vectored Zaire Ebola vaccine (rVSV-ZEBOV). The overall objective of VSV-EBOVAC is to comprehensively characterize the signatures of immune responses elicited in humans by the rVSV-ZEBOV vaccine using cutting-edge technologies combining in-depth human immune, transcriptomics and metabolomics profiling in relation to safety and immunogenicity.

VSV-EBOVAC is a public-private consortium of 12 partners involving experts from academic institutions, scientists of the 3 main clinical sites (Switzerland, Gabon, Kenya), the vaccine manufacturer, a small and medium-sized enterprises (SMEs) and research institutes. 

VSV-EBOVAC started in March 2015, is a 3 years project funded by the Innovative Medicine Initiative 2 Joint Undertaking (IMI 2 JU). 

 

Project Description

VSV-EBOVAC started in March 2015, is a 3-year project and has received funding from the European Union's Horizon 2020. Read more

 

 

Research Partners

Scientists from 7 countries and 12 research partners collaborate in the VSV-EBOVAC project.

 

News & Events News & Events

Advanced Course in Flow Cytometry Applied to Vaccinology

From 11 th -14 th  September 2017 , Siena, Italy.  Organized by the University of Siena and directed by Dr . Sandra Nuti.     The advanced course in flow cytometry...

VSV-EBOVAC identifies signature of promising Ebola vaccine

How exactly does our immune system respond to vaccination? In the first study of its kind, scientists from IMI's VSV-EBOVAC project, studying a promising Ebola vaccine, set out to find out which...

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine

The article "Immunomonitoring of human responses to the rVSV-ZEBOV Ebola Vaccine" was published in Current Opinion in Virology journal with the acknowledgment of the VSV-EBOVAC Consortium. It...

Dose-dependent plasma signature of innate immune responses to rVSV-ZEBOV reflects its biological outcomes and safety

VSV-EBOVAC Consortium reports that a dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and safety in Europe and Africa The...

Research Topic "Advanced Immunization Technologies for Next Generation Vaccines" to be published in Frontiers in Immunology

A Research Topic "Advanced Immunization Technologies for Next Generation Vaccines” is to be published in Frontiers in Immunology, Section Vaccines and Molecular Therapeutics.  Scientists...